BPC-157 Oral (Gut) vs Larazotide
A side-by-side research comparison of BPC-157 Oral (Gut) and Larazotide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 Oral (Gut) | Larazotide |
|---|---|---|
| Full name | BPC-157 Oral (Stable Arginine Salt) | Larazotide Acetate (AT-1001) |
| Category | Gut Health | Gut Health |
| Status | Research compound | Investigational (Phase 3) |
| Mechanism | Upregulates VEGF and EGF receptors in GI mucosa, promotes angiogenesis at ulcer/lesion sites, modulates nitric oxide system, and interacts with dopamine and serotonin systems in the gut-brain axis. | Acts as a zonulin peptide antagonist, preventing zonulin-mediated disassembly of tight junction proteins (ZO-1, occludin, claudins). Maintains paracellular barrier integrity without systemic absorption. |
| Molecular weight | 1419 Da | 1026 Da |
| Half-life | ~4 hours (local GI transit) | Not systemically absorbed (local GI action) |
| Bioavailability | Limited systemic absorption; primary action is local GI | Minimal systemic absorption (acts locally in GI lumen) |
| Typical dose | 250-500 mcg | 0.5-1 mg |
| Frequency | 2x daily on empty stomach | 3x daily before meals |
| Route | Oral capsule or sublingual | Oral capsule |
BPC-157 Oral (Gut) reported benefits
- Gastric ulcer healing
- Esophageal repair (GERD)
- Intestinal inflammation reduction
- IBD symptom relief
- Gut-brain axis support
- NSAID damage protection
Larazotide reported benefits
- Reduced intestinal permeability
- Decreased GI symptoms
- Tight junction restoration
- Reduced systemic inflammation from gut
- Improved gluten tolerance
Related comparisons
Research and educational reference only. Not medical advice.